Rotation thromboelastometry (ROTEM®) stability and reproducibility over time 
Introduction
Rotation thromboelastometry (ROTEM®) (ROTEM® delta, Pentapharm GmbH, München, Germany), a methodology based on thromboelastography originally described by Hartert more than 50 years ago [1] , is frequently used today to rapidly assess the viscoelastic properties of the developing clot in cardiac and transplant surgery as well as following trauma. [2] [3] [4] [5] ROTEM® documents the interaction of platelets with the coagulation factors from initial platelet-fibrin interaction, through platelet aggregation, clot strengthening, and fibrin cross-linking, to eventual clot lysis. Within 30 minutes, a ROTEM® tracing provides information on clotting factor activity, platelet function, and any clinically significant fibrinolysis. [6, 7] The goal of this study was to assess stability and reproducibility over time of ROTEM®. The lake of such a study was already mentioned by Dunning et al. [8] in 2008 and by Samama et al. [9] in 2003. Possible changes due to age and sex were also of interest. In thrombelastography (TEG® Haemoscope Corporation, Skokie, IL, USA), stability of results over time is only achieved following a thirty minute waiting time after blood draw and before analysis. [10] Immediate sample analysis however is desirable in the setting of an acute bleeding event. We thus assessed stability over time for ROTEM®.
Material and Methods
This clinical trial was performed after obtaining authorization by the local ethic committee (Kantonale Ethikkommission, Kanton Zürich, Switzerland, Study number StV 27-2007).
Sample size (n=48) was chosen based on statistical considerations and on reported general practice. Horn et al. showed that a minimum of 39 patients is needed for establishing a 95 % reference interval by power analysis. [11] In addition, Friedberg et al. reported in 2007 [12] , that 50% of laboratories establish enrol 21-50 subjects when establishing reference intervals As a possible age or gender effect was of interest, three male and three female patients in each of the following eight age categories were included: Below 20 years; 20 -30 years; 30 -40 years; 40 -50 years; 50 -60 years; 60 -70 years, 70 -80 years and above 80 years.
Inclusion criteria were: Scheduled for a non-emergent operation and signed written informed consent. Exclusion criteria were: Known malignancy or immunosupression, known coagulation disorders, anticoagulation in any form, current treatment with heparin (other than routine preoperative thromboembolic prophylaxis with 3,000 IU low-molecular-weight heparin administered subcutaneously the evening prior to the operation), use of acetyl salicylic acid within the past 5 days, use of nonsteroidal anti-inflammatory agents within the past 24 h, known renal diseases or plasma concentration of creatinine more than 120 mM and liver diseases or increased plasma concentration of aspartate aminotransferase (> 50 U/l) or alanine aminotransferase (> 50 U/l) as well as patients not capable of understanding the German language .
The study's main objectives were to validate ROTEM® by investigating 1) pre-analytic aspects (sample stability), 2) reproducibility and precision of ROTEM® (intra and inter assay variability) and 3) reference intervals and effect of age and sex.
Several predefined tests were assessed: INTEM (ellagic acid activated intrinsic pathway), EXTEM (tissue factor triggered extrinsic pathway) and FIBTEM (with platelet inhibitor (cytochalasin D) evaluating the contribution of fibrinogen to clot formation). These three assays are performed in citrated samples and represent counterparts of routine tests of plasmatic coagulation: fibrinogen, prothrombin time, activated partial thromboplastin time.
The two main differences between thromboelastometric tests and plasmatic coagulation tests are i) the former is performed on whole blood, the latter on plasma and ii) the former measures processes involving thrombin generation, clot formation and clot lysis, the latter processes leading up and until the initial generation of thrombin. By utilising inhibitors of platelet function the developers of the assay have derived a functional test of fibrinogen, called FIBTEM. This can be correlated with functional fibrinogen tests in plasma. By comparing the EXTEM, the thrombelastometric test that utilizes tissue factor (comparable to the prothrombin time test) as an activator, with the FIBTEM, one can deduce relevant information regarding platelet function and factor XIII function, as both of these contribute to the EXTEM measurement.
In EXTEM the extrinsic pathway is activated by thromboplastin from rabbit brain to assess clot formation and fibrinolysis. In INTEM the intrinsic pathway is activated by a contact activator to assess the clot formation and fibrin polymerization. In FIBTEM the extrinsic pathway is activated by tissue factor in presence of a platelet inhibitor to assessment the functional fibrinogen level.
A number of ten volunteers were sufficient to investigate precision and reproducibility according to power analysis with 95 % confidence interval (CI). To investigate precision and reproducibility of ROTEM® analysis, for inter-assay (on one single ROTEM® device) reproducibility testing was performed in 10 volunteers, after having obtained written informed consent, withdrawing 3 tubes (Vacutainer Brand, Belliver Industrial Estate, Plymouth, UK, 4.5 ml, 9 NC 0.129 M, a total of 18 ml per volunteer) of citrated blood, the first tube (Vacutainer Brand, Belliver Industrial Estate, Plymouth, UK, 4.5 ml, 9 NC 0.129 M) drawn was discarded to exclude coagulation activation due to vein puncture and blood withdrawal.
Inter-device variability was tested using the same samples on a second ROTEM® device.
Intra-assay variability was tested by performing duplicate measurements at the time of the first blood draw on the same device using different channels and calculating the coefficient of Measurements for this test series ran for 60 minutes.
Parameters of Rotation Thromboelastometry
ROTEM® defines various parameters to describe the dynamics, the size and the firmness of clot during clot formation and lysis ( 
Test procedure
All ROTEM® devices used in this study were new and set up by a representative of the local distributor. The tests were performed using the automated pipette programs according to the instructions of the manufacturer. For each measurement a new pin was positioned on the axis of the measurement channel and a new cup was put into the special cup holder of the device. Then 300 µl of citrated whole blood was added to the cup and, after a semi-automated mixing step, the cup holder was placed to the measuring position of the ROTEM® device. The measurement started automatically when blood was added to the cup and was stopped after 30 
Results

Baseline information:
The 48 patients had a mean age of 50±22 years, ranging from 17 to 87 years. For the 24 women the mean age was 50±22 years, ranging from 17 to 85 years. For the 24 men the mean age was 50±22 years, ranging from 17 to 87 years. The 10 volunteers were 5 men and 5 women, the overall mean age was of 37±14 years, ranging from 20 to 63 years.
Pre-analytic aspects stability over time:
Over the time of 120 minutes there was no significant difference between any parameter in EXTEM, INTEM and FIBTEM, indicating that ROTEM® measurements are stable over two hours at room temperature. (Table 1 Reference intervals: Reference intervals were calculated according to international guidelines by means and adding one standard deviation on each side. We also calculated reference intervals by gender. (Table 3) We were able to show that reference intervals calculated in this study were closer together then by the manufacturer. A gender specific influence is also to be seen. 
Effect of age and gender:
Discussion
Our analysis of pre-analytic aspects showed that ROTEM® tests yield stable results from citrated blood that was re-calcified during the first 120 minutes. This is of high practical relevance since the exact delay from blood drawing to testing would be difficult to standardize, particularly in major trauma. This is in contrast to the thrombelastography where a previous report showed that parameters are unstable in the first 30 minutes after blood draw. Compared with the results of Lang et al. [13] we have found a somewhat lower variability for the maximum clot firmness in the FIBTEM test (coefficient of variability for maximum clot firmness < 6%). This may be due to the fact that in our study only three persons performed all ROTEM® tests, which is impossible when pooling data from different centres. Performing ROTEM® tests by persons being really familiar the ROTEM® technology thus appears to reduce the variability.
A progressive change of the ROTEM® parameters towards hypercoagulability with advancing age as observed in this study has also been described by Ng et al. [14] for thrombelastography (TEG® Haemoscope Corporation, Skokie, IL, USA), and is in keeping with previous reports describing hypercoagulability in elderly people [14, 15] Since the ROTEM® parameters measured in the current study were still within the reference ranges provided by the manufacturer an age specific adaptation of the reference ranges may not be required for ROTEM®. Nevertheless the trend of increased clot firmness at advanced age should be kept in mind in the clinical interpretation of ROTEM® results.
We found differences between men and women in ROTEM® parameters which suggest a faster development of the clot and greater clot strength in women as compared with men (table 4) . Unfortunately, no measures of fibrinogen according to Clauss were performed in this study. Nevertheless, this may represent a factor predisposing women to thrombotic complications. [16] A limitation of this study is that we did not take into account the effective temperature in patients since it is known to impair results and interpretation of ROTEM® [17] . We think that this point is of limited importance since the ROTEM® devices work at a temperature of 37 °C and the 300 µL of blood are at this temperature and patient were not hypothermic at the moment when blood was drawn.
ROTEM® results cannot give exact recommendations on the amount of blood products or coagulation factors to be administered. However, ROTEM® can guide the clinician which type of treatment may be most helpful to treat coagulopathy during surgery or in trauma. In 2007 Rugeri et al. showed in trauma patients that ROTEM® can rapidly detect trauma related coagulopathy and might be helpful to guide treatment [18] . Theusinger et al. [19] published a ROTEM® based transfusion algorithm to guide individual goal directed transfusions. A retrospective analysis by Anderson et al. [20] in 990 patients showed that the use of ROTEM® significantly decreases the use of red blood cells and other blood products after cardiac surgery. This is particularly important given the fact that red blood cell transfusion in cardiac surgery is consistently associated with significant morbidity an increased mortality.
[21-24]Last but not least, Spalding et al. have demonstrated that a ROTEM® based coagulation algorithm decreased total transfusion costs in cardiac surgery [25] .
Conclusion
ROTEM® measurements of EXTEM, INTEM and FIBTEM are reproducible and stable over time regardless of delay form blood draw to analysis (range 0 to 120 minutes after blood withdrawal). There is a high reproducibility with the coefficient of variation < 6 % in all assays. Coefficient of variation for maximum clot firmness in EXTEM was < 3%, INTEM < 5% and FIBTEM <6% are small but statistically significant. With age there is a tendency of hypercoagulability and gender (sex) women seem to coagulate better then men but within range. To avoid problems in treating coagulopathies when working with an algorithm or to interpret the evolution of ROTEM® parameters over time ROTEM® tests should preferably be performed on the same ROTEM® device since in our study one ROTEM® device yielded slightly but statistically significantly different results for maximum clot firmness and clot formation time. 
